Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 1
2008 2
2009 2
2010 2
2011 2
2014 1
2015 3
2016 2
2017 1
2022 1
2023 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Dose-related patterns of glucocorticoid-induced side effects.
Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Huscher D, et al. Among authors: demary w. Ann Rheum Dis. 2009 Jul;68(7):1119-24. doi: 10.1136/ard.2008.092163. Epub 2008 Aug 6. Ann Rheum Dis. 2009. PMID: 18684744
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Burmester GR, Kofler DM, Brandt J, Finzel S, Bergner R, Sieburg M, Behrens F; MUST Investigator Group. Koehm M, et al. RMD Open. 2023 Dec 19;9(4):e003538. doi: 10.1136/rmdopen-2023-003538. RMD Open. 2023. PMID: 38114198 Free PMC article.
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Wendler J, Schuch F, Ronneberger M, Lorenz HM, Nuesslein H, Alten R, Demary W, Henes J, Schett G, Rech J. Haschka J, et al. Among authors: demary w. Ann Rheum Dis. 2016 Jan;75(1):45-51. doi: 10.1136/annrheumdis-2014-206439. Epub 2015 Feb 6. Ann Rheum Dis. 2016. PMID: 25660991 Clinical Trial.
20 results